Squarepoint
KRSA

Squarepoint’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Squarepoint’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-978
Closed -$372K – 1991
2019
Q4 		$372K Buy
978
+342
+54% +$31.9K ﹤0.01% 1920
2019
Q3 		$1.08M Buy
636
+268
+73% +$57.9K 0.01% 1183
2019
Q2 		$590K Buy
+368
New +$104K 0.01% 1563

Other funds holding KRSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Squarepoint's KRSA Position: Q1 2020 in Review

Squarepoint sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q1 2020, closing a stake of 978 shares — an estimated $372K sold.

Squarepoint first reported a position in KRSA in Q2 2019 and held it in 3 quarters. The position peaked at $1.08M in Q3 2019. 74 funds tracked by Wall St. Rank hold KRSA as of Q1 2020.

  • Squarepoint reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Squarepoint sold 978 Korsana Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $372K.
  • Squarepoint first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Squarepoint's Korsana Biosciences, Inc. Common Stock position peaked at $1.08M in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q1 2020.

Based on Squarepoint's 13F filing for Q1 2020, filed 15 May 2020.